Clinical trials: Cortisol; Hypersecretion
Cushing Disease
Hair Cortisol and Cushing's Disease
The biochemical tools usable to assess the control of hypercortisolism in patients with Cushing's disease receiving medical treatments are debatable.
- Trial name
- HAIRCUSH (NCT04201444)
- Testing
- Patient group, Remission control group, Bilateral surrenalectomy control group
- Where
- 7 sites in France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Bordeaux
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Metabolic Syndrome, Hypersecretion; Cortisol
Effects of IL-1 Beta on the HPA-axis in Obese Persons
In obese individuals cortisol production and secretion is increased but the underlying mechanism is not known. Obesity leads to a pathological activation of the innate immune system partly driven by tissue production of IL-1β.
- Trial name
- CortIL (NCT02227420)
- Testing
- Anakinra
- Where
- Switzerland
- Volunteers
- 76 people
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes Mellitus, Type 2, Obesity
Type 2 Diabetes, Obesity and Cortisol Excess
The present observational cross-sectional study is aimed to assess: the hidden hypercortisolism (HidHyCo) prevalence in a sample of Type 2 diabetes (T2D) patients and the clinical characteristics more frequently associated with…
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Cortisol; Hypersecretion
- Trial name
- DOCOR (NCT05759637)
- Testing
- 1mg DST
- Where
- 5 sites in Italy
- Volunteers
- 3,200 people
- Sponsor
- Istituto Auxologico Italiano
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics
Acute Coronary Syndrome, Stress Hyperglycemia
Cellular Immunity, Neuroendocrine, and Inflammatory Factors for Clinical Prognosis in Acute Coronary Syndrome
In acute coronary syndrome (ACS), there is an increase in cortisol levels, as an expression of the stress response, and C-reactive protein, as an expression of the inflammatory response, which are in turn associated with changes…
- Conditions
- Acute Coronary Syndrome, Stress Hyperglycemia, Cortisol; Hypersecretion, Inflammatory Response
- Trial name
- NCT06513611
- Testing
- Serum cortisol.
- Where
- Argentina
- Volunteers
- 150 people
- Sponsor
- Hospital de Clinicas José de San Martín
Cushing Syndrome
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per…
- Trial name
- NCT04543253
- Testing
- MUSE biofeedback
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Mayo Clinic
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor.
- Conditions
- Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion
- Trial name
- RESCUE (NCT05307328)
- Testing
- SPI-62
- Where
- 12 sites in United States, Bulgaria and 1 more
- Volunteers
- 26 people
- Sponsor
- Sparrow Pharmaceuticals
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Cushing's Disease
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
- Trial name
- SEASCAPE (NCT01582061)
- Testing
- Pasireotide sub-cutaneous
- Where
- 65 sites in United States, Brazil and 9 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Cushing Disease
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma.
- Trial name
- NCT00171951
- Testing
- Pasireotide
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Stress, Cortisol; Hypersecretion
Effect of Maternal Cortisol Levels on Fetal Heart Rate Patterns
Objective: This study was designed to determine whether maternal cortisol levels affect fetal heart rate (FHR) patterns at third trimester. Design: Cross-sectional descriptive study.
- Conditions
- Stress, Cortisol; Hypersecretion, Fetal Heart Rate Disorder
- Trial name
- NCT05503433
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Halic University
Ischemic Stroke, Cortisol; Hypersecretion
Neuroactive Steroids in Acute Ischemic Stroke
Acute ischemic stroke (AIS) represents an economical challenge for health systems all over the globe. Despite increasing knowledge of the pathophysiology of AIS, there is no satisfactory treatment to revert the resulting brain…
- Trial name
- Cortisol (NCT03242304)
- Testing
- Behavioral tests
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Militar Central, Argentina
Cushing Syndrome, Adrenal Insufficiency
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
This is a multicentric, prospective, intervention study on circadian genes expression in peripheral blood mononuclear cells as biomarkers of circadian rhythm derangement in patients affected by alterations of endogenous…
- Conditions
- Cushing Syndrome, Adrenal Insufficiency, Cushing Disease, Addison Disease
- Trial name
- CHROnOS (NCT04374721)
- Testing
- circadian gene expression evaluation
- Where
- Italy
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Stress, Emotional, Dental Anxiety
Salivary Immune/Stress Biomarkers Among Children
Background: The use of easily accessible biomarkers for assessing young patients' health is important. This study's aim is a measuring stress/immune biomarkers in saliva of healthy school-age children and compare subgroups…
- Conditions
- Stress, Emotional, Dental Anxiety, Dental Pain and Sensation Disorder, Cortisol; Hypersecretion
- Trial name
- OPI2 (NCT05021380)
- Testing
- GROUP
- Where
- Poland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Poznan University of Medical Sciences
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Sleep Disturbance, Craving
The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial
Insomnia is an extremely common and poorly treated problem in patients with substance use disorders (SUD)s undergoing rehabilitation treatment in a residential facility.
- Conditions
- Sleep Disturbance, Craving, Cortisol; Hypersecretion
- Trial name
- Suvsubuse (NCT03412591)
- Testing
- Suvorexant 20 mg
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Milton S. Hershey Medical Center
Disorder of Endocrine Ovary, Hypersecretion; Cortisol
Pathogenesis of Functional Hypothalamic Amenorrhea
This is a randomized pilot study of the use of cognitive behavior therapy versus observation to treat functional hypothalamic amenorrhea, often termed stress-induced anovulation.
- Conditions
- Disorder of Endocrine Ovary, Hypersecretion; Cortisol, Metabolic Disturbance, Stress, Psychological
- Trial name
- NCT01674426
- Testing
- Cognitive behavior therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Pittsburgh
Cushing Disease Due to Increased ACTH Secretion
Combination Osilodrostat and Cabergoline in Cushing's Disease
Cushing disease remains a challenging endocrine disorder in which persistent or recurrent hypercortisolism often requires medical therapy after surgery or when surgery is not feasible.
- Trial name
- COSCA-ECD (NCT07603466)
- Testing
- osilodrostat, osilodrostat and cabergoline
- Where
- 5 sites in Iraq
- Volunteers
- 50 people
- Sponsor
- University of Basrah